Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytome

Trial Details

NCT ID
NCT06967961
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
Locations (sample)
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • 1\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carc…
  • 2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
  • 3\. Age ≥ 18 years
  • 4\. Patient affiliated to a French Social Security scheme

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →